口服乌帕替尼单药治疗顽固性白癜风患者的疗效和耐受性。 - Suppr

Suppr

超能文献

Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo.

作者信息

Su Xinhong, Luo Renwei, Ruan Shifan, Zhong Qingmei, Zhuang Zheyu, Xiao Zhixun, Zhang Peng, Cheng Bo, Gong Ting, Ji Chao

机构信息

Department of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.

Central Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.

出版信息

J Am Acad Dermatol. 2023 Dec;89(6):1257-1259. doi: 10.1016/j.jaad.2023.07.1016. Epub 2023 Jul 28.

DOI:10.1016/j.jaad.2023.07.1016

PMID:37516357

Abstract

摘要

相似文献

Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo.口服乌帕替尼单药治疗顽固性白癜风患者的疗效和耐受性。

J Am Acad Dermatol. 2023 Dec;89(6):1257-1259. doi: 10.1016/j.jaad.2023.07.1016. Epub 2023 Jul 28.

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.乌帕替尼单药治疗对甲氨蝶呤应答不足的活动性类风湿关节炎患者（SELECT-MONOTHERAPY）：一项随机、安慰剂对照、双盲 3 期研究。

Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23.

Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study.Upadacitinib 单药治疗与甲氨蝶呤单药治疗对初治类风湿关节炎日本患者的疗效比较：III 期 SELECT-EARLY 研究的亚分析。

Mod Rheumatol. 2021 May;31(3):534-542. doi: 10.1080/14397595.2020.1847776. Epub 2021 Jan 26.

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.乌帕替尼治疗生物制剂难治的活动性类风湿关节炎患者的安全性和疗效（SELECT-BEYOND）：一项双盲、随机对照 3 期临床试验。

Lancet. 2018 Jun 23;391(10139):2513-2524. doi: 10.1016/S0140-6736(18)31116-4. Epub 2018 Jun 18.

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.在有心血管疾病风险的患者中，upadacitinib 的安全性特征：SELECT Ⅲ期类风湿关节炎临床项目的事后综合分析。

Ann Rheum Dis. 2023 Sep;82(9):1130-1141. doi: 10.1136/ard-2023-223916. Epub 2023 Jun 12.

Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.比较托法替布、巴瑞替尼、乌帕替尼和氟可替尼与甲氨蝶呤在类风湿关节炎初治患者中的疗效和安全性。

Z Rheumatol. 2021 Nov;80(9):889-898. doi: 10.1007/s00393-020-00889-x. Epub 2020 Sep 24.

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.乌帕替尼治疗活动性强直性脊柱炎患者的疗效和安全性（SELECT-AXIS 1）：一项多中心、随机、双盲、安慰剂对照、2/3 期临床试验。

Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.Upadacitinib 在日本类风湿关节炎患者中的疗效和安全性（SELECT-SUNRISE）：一项安慰剂对照的 IIb/III 期研究。

Rheumatology (Oxford). 2020 Nov 1;59(11):3303-3313. doi: 10.1093/rheumatology/keaa084.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.乌帕替尼治疗对常规合成改善病情抗风湿药物应答不足的类风湿关节炎患者的安全性和疗效（SELECT-NEXT）：一项随机、双盲、安慰剂对照的 3 期临床试验。

Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.乌帕替尼或阿巴西普治疗类风湿关节炎的试验。

N Engl J Med. 2020 Oct 15;383(16):1511-1521. doi: 10.1056/NEJMoa2008250.

引用本文的文献

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo.口服乌帕替尼-外用芦可替尼联合疗法治疗进展期非节段型白癜风的疗效和安全性

JAAD Int. 2025 Jun 12;22:16-19. doi: 10.1016/j.jdin.2025.04.014. eCollection 2025 Oct.

Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis.JAK抑制剂治疗白癜风的疗效与安全性：一项系统评价和Meta分析

Dermatol Ther (Heidelb). 2025 May 7. doi: 10.1007/s13555-025-01397-z.

Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone.乌帕替尼单药治疗与特应性皮炎相关的白癜风：一石二鸟。

Case Rep Dermatol. 2025 Feb 28;17(1):91-95. doi: 10.1159/000544703. eCollection 2025 Jan-Dec.

A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment.口服托法替布治疗活动性白癜风的疗效和安全性回顾性分析。

Arch Dermatol Res. 2025 Mar 28;317(1):645. doi: 10.1007/s00403-025-04151-9.

Emerging Therapeutic Innovations for Vitiligo Treatment.白癜风治疗的新兴治疗创新

Curr Issues Mol Biol. 2025 Mar 14;47(3):191. doi: 10.3390/cimb47030191.

Knowledge, attitude, and practice toward vitiligo among vitiligo patients: a mediation analysis.白癜风患者对白癜风的知识、态度和行为：一项中介分析

Sci Rep. 2025 Feb 8;15(1):4741. doi: 10.1038/s41598-025-89346-w.

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta-Analysis.白癜风患者中 Janus 激酶抑制剂的疗效与安全性：一项系统评价与荟萃分析

Clin Pharmacol Ther. 2025 Mar;117(3):659-669. doi: 10.1002/cpt.3538. Epub 2024 Dec 23.

Repigmentation in non-segmental vitiligo using the Janus kinase inhibitor upadacitinib, a retrospective case series.使用JAK激酶抑制剂乌帕替尼治疗非节段型白癜风的色素再生：一项回顾性病例系列研究

Arch Dermatol Res. 2024 Dec 20;317(1):143. doi: 10.1007/s00403-024-03658-x.

Low-Dose Baricitinib Plus Narrow-Band Ultraviolet B for the Treatment of Progressive Non-Segmental Vitiligo: A Prospective, Controlled, Open-Label Study.低剂量巴瑞替尼联合窄谱中波紫外线治疗进展期非节段型白癜风：一项前瞻性、对照、开放标签研究。

Pigment Cell Melanoma Res. 2025 Jan;38(1):e13209. doi: 10.1111/pcmr.13209. Epub 2024 Oct 23.

Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications.细胞因子和趋化因子在白癜风中的作用及其治疗意义

J Clin Med. 2024 Aug 20;13(16):4919. doi: 10.3390/jcm13164919.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验